The effect of non-AIDS-defining cancers on people living with HIV
| Autor: | Angela L. Mazul, Anna Coghill, Keith Sigel, Darya Kizub, Elizabeth Y. Chiao, Ntokozo Ndlovu, Valeria Fink |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Psychological intervention Human immunodeficiency virus (HIV) HIV Infections medicine.disease_cause 03 medical and health sciences Prostate cancer 0302 clinical medicine Acquired immunodeficiency syndrome (AIDS) Risk Factors Antiretroviral Therapy Highly Active Neoplasms Medicine Humans 030212 general & internal medicine Intensive care medicine Sarcoma Kaposi Acquired Immunodeficiency Syndrome business.industry Incidence (epidemiology) Cancer HIV Guideline medicine.disease Treatment Outcome Oncology Infectious disease (medical specialty) 030220 oncology & carcinogenesis Immunotherapy business |
| Zdroj: | The Lancet. Oncology. 22(6) |
| ISSN: | 1474-5488 |
| Popis: | Non-AIDS-defining cancers are a growing source of morbidity for people with HIV globally. Although people living with HIV have a disproportionately increased risk of developing virally mediated cancers, cancer burden for common non-AIDS-defining cancers that are not virally associated and are linked to ageing, such as prostate cancer, is becoming higher than for virally mediated cancers. Ageing, behavioural, and HIV-specific factors drive the incidence and affect the outcomes of non-AIDS-defining cancers, presenting different challenges for addressing global morbidity and mortality from non-AIDS-defining cancer. Although large population-based studies have shown that people living with HIV with non-AIDS-defining cancers have poorer cancer outcomes than do people without HIV, current guidelines emphasise that people living with HIV with non-AIDS-defining cancers should receive standard, guideline-based treatment, and infectious disease and oncology providers should work closely to address potential drug interactions between antiretroviral therapy and antineoplastic treatment. Most trials target preventive measures focusing on non-AIDS-defining cancers. However, treatment trials for the optimal management of people living with HIV and non-AIDS-defining cancer, including interventions such as immunotherapies, are needed to improve non-AIDS-defining cancer outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|